Why was primary biliary cirrhosis renamed primary biliary cholangitis?

The original name emphasised cirrhosis, the disease's late stage, but most patients are now diagnosed long before cirrhosis develops; the term was changed to primary biliary cholangitis to describe the underlying inflammation of the bile ducts rather than the end-stage scarring.

What antibody is characteristic of PBC?

Antimitochondrial antibodies, typically directed against the E2 subunit of the pyruvate dehydrogenase complex, are found in the large majority of people with PBC and are a defining serologic feature of the disease.

Primary Biliary Cholangitis (PBC)

Primary biliary cholangitis, formerly called primary biliary cirrhosis, is a chronic autoimmune cholangiopathy in which the small intrahepatic bile ducts are progressively destroyed. The resulting intrahepatic cholestasis can, over years, advance to fibrosis and cirrhosis. It is strongly associated with antimitochondrial antibodies and a cholestatic biochemical pattern.

Definition

Primary biliary cholangitis is a chronic, progressive autoimmune liver disease characterised by lymphocytic destruction of the small intrahepatic bile ducts, leading to intrahepatic cholestasis and, in advanced stages, to biliary fibrosis and cirrhosis, typically in the presence of antimitochondrial antibodies.

Scope

The topic covers the autoimmune destruction of the small bile ducts, the antimitochondrial antibody that characterises the disease, the cholestatic and immunologic features used to recognise it, and its natural history toward biliary fibrosis. It is a reference description of the disease entity, not individualised clinical guidance.

Core questions

What is the target of the autoimmune injury in PBC, and why are small bile ducts destroyed?
How do antimitochondrial antibodies relate to the disease?
How does the chronic destruction of small ducts produce cholestasis and progress to fibrosis?
What features distinguish PBC from other cholestatic and autoimmune liver diseases?

Key concepts

Autoimmune cholangiopathy
Antimitochondrial antibodies (AMA) and the PDC-E2 antigen
Non-suppurative destructive cholangitis of small ducts
Intrahepatic cholestasis
Ductopenia
Progression to biliary fibrosis and cirrhosis
Association with other autoimmune conditions

Mechanisms

PBC is driven by an immune attack on the epithelial cells of the small intrahepatic bile ducts. The hallmark serologic marker is the antimitochondrial antibody directed against the E2 component of the pyruvate dehydrogenase complex (PDC-E2), and the characteristic histology is a non-suppurative destructive cholangitis with lymphocytic infiltration of the portal tracts. Progressive loss of small ducts (ductopenia) impairs bile drainage and produces intrahepatic cholestasis, with retention of bile acids that further injures hepatocytes and cholangiocytes. Over years the chronic injury drives periportal inflammation and fibrosis that can culminate in biliary cirrhosis. The disease is markedly more common in women and frequently coexists with other autoimmune disorders.

Clinical relevance

PBC is a leading cause of chronic intrahepatic cholestasis and is recognised through a cholestatic enzyme pattern together with antimitochondrial antibodies, making it a reference example of autoimmune cholangiopathy. This entry describes the disease for educational purposes and is not a basis for individual diagnostic, monitoring, or treatment decisions; management is addressed by clinical practice guidelines.

Epidemiology

PBC predominantly affects middle-aged women, with a strong female preponderance, and is uncommon overall though its recognised prevalence has risen with antibody testing. It is one of the more frequent autoimmune liver diseases and a recognised indication, in advanced disease, for evaluation toward liver transplantation.

History

The condition was long called primary biliary cirrhosis after its advanced fibrotic stage, but because most patients are identified well before cirrhosis develops, the disease was renamed primary biliary cholangitis to reflect the underlying cholangitis rather than its end stage. The discovery of antimitochondrial antibodies and the identification of the PDC-E2 autoantigen were pivotal in defining the disease as an autoimmune cholangiopathy.

Seminal works

kaplan-2005
carey-2015
hirschfield-2017
lleo-2020

Frequently asked questions

Why was primary biliary cirrhosis renamed primary biliary cholangitis?: The original name emphasised cirrhosis, the disease's late stage, but most patients are now diagnosed long before cirrhosis develops; the term was changed to primary biliary cholangitis to describe the underlying inflammation of the bile ducts rather than the end-stage scarring.
What antibody is characteristic of PBC?: Antimitochondrial antibodies, typically directed against the E2 subunit of the pyruvate dehydrogenase complex, are found in the large majority of people with PBC and are a defining serologic feature of the disease.